Osmetech to aid Doctors in Warfarin Therapy

 

TIDMOMH 
 
 
Osmetech PLC 
08 June 2009 
 
? 
8 June 2009 
 
 
Osmetech plc ("Osmetech" or the "Company") 
 
 
Osmetech's exclusive Warfarin CYP4F2 biomarker included in leading 
warfarindosing.org algorithm 
 
 
Osmetech plc (OMH.L), the international molecular diagnostics company, announces 
that its' exclusive CYP450 4F2 biomarker has been included on the leading 
warfarin dosing website, www.warfarindosing.org  a free Web site to aid doctors 
and other clinicians in warfarin therapy by estimating the therapeutic dose in 
patients new to warfarin or within first 4 INR's. 
 
 
James White, Chief Executive Officer, Osmetech plc, said: 
 
 
"The inclusion of 4F2, exclusively licensed to Osmetech, is further recognition 
of the importance of the biomarker's role in establishing a safe and appropriate 
personalized dose for each patient." 
 
 
"The high performance of our eSensor XT-8 System and Warfarin Sensitivity Test 
in the market combined with our unique 4F2 biomarker gives us 'best platform' 
and 'best test'.  This combination further positions Osmetech as the leader in 
this market, which we believe is poised for significant growth." 
 
 
 
 
Osmetech plc [phone] 
James White, Chief Executive Officer    [phone] 
David Sandilands, Chief Financial Officer 
Geoff McKinley, Vice President Business Development 
 
 
 
 
Warfarin sensitivity testing 
 
 
Warfarin is an oral anticoagulant widely used for the prevention of thrombotic 
events and to treat a confirmed episode of venous thrombosis, with approximately 
2 million new patients each year in the US alone. Although highly effective, 
warfarin's usability is limited by a narrow therapeutic range combined with a 
pronounced interindividual variability in the dose required for adequate 
anticoagulation. Clinical use of warfarin is further complicated by a 
substantial risk for hemorrhagic side effects, which is increased in patients 
with low-dose requirements. Warfarin is the second-most-likely drug, after 
Digoxin, to cause adverse events requiring hospitalization. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 NRAVVLBBKQBEBBL